DexCom Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . DexCom Inc
DXCM Stock  USD 73.08  0.92  1.24%   
DexCom's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing DexCom's valuation are provided below:
Gross Profit
2.7 B
Profit Margin
0.1596
Market Capitalization
29 B
Enterprise Value Revenue
6.1704
Revenue
4.5 B
There are over one hundred nineteen available fundamental signals for DexCom Inc, which can be analyzed over time and compared to other ratios. Self-guided Investors are advised to verify DexCom's prevailing fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 30th of January 2026, Market Cap is likely to grow to about 267.1 M. Also, Enterprise Value is likely to grow to about 231.9 M

DexCom Total Revenue

4.87 Billion

Check DexCom financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among DexCom's main balance sheet or income statement drivers, such as Interest Expense of 12.2 M, Other Operating Expenses of 4.1 B or Operating Income of 724.5 M, as well as many indicators such as Price To Sales Ratio of 8.52, Dividend Yield of 0.0 or PTB Ratio of 10.1. DexCom financial statements analysis is a perfect complement when working with DexCom Valuation or Volatility modules.
  
Build AI portfolio with DexCom Stock
Check out the analysis of DexCom Correlation against competitors.

DexCom Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets7.8 B7.5 B2.9 B
Slightly volatile
Cash731.9 M697 M438.7 M
Slightly volatile
Cash And Short Term Investments3.1 B3 B1.4 B
Slightly volatile
Common Stock Shares Outstanding254.7 M474.6 M333.2 M
Slightly volatile
Liabilities And Stockholders Equity7.8 B7.5 B2.9 B
Slightly volatile
Total Current Assets5.2 B4.9 B2.1 B
Slightly volatile
Other Current Liabilities1.6 B1.5 B457.9 M
Slightly volatile
Total Current Liabilities3.5 B3.4 B916.1 M
Slightly volatile
Property Plant And Equipment Net1.7 B1.6 B558.8 M
Slightly volatile
Accounts Payable416.9 M397.1 M145.4 M
Slightly volatile
Non Current Assets Total2.6 B2.5 B829.7 M
Slightly volatile
Non Currrent Assets Other64.8 M61.8 M18.6 M
Slightly volatile
Other Assets445.9 M424.7 M145.7 M
Slightly volatile
Common Stock Total Equity483 K460 K189 K
Slightly volatile
Non Current Liabilities Total1.8 B1.7 B915.9 M
Slightly volatile
Total Liabilities5.3 B5 B1.8 B
Slightly volatile
Property Plant And Equipment Gross2.5 B2.4 B717.6 M
Slightly volatile
Common Stock483 K460 K206.7 K
Slightly volatile
Property Plant Equipment1.4 B1.3 B493.5 M
Slightly volatile
Other Liabilities83 M79 M34.7 M
Slightly volatile
Short Term Investments2.4 B2.3 B930.8 M
Slightly volatile
Short and Long Term Debt Total3.1 B3 B1.2 B
Slightly volatile
Net Receivables1.2 B1.2 B416.4 M
Slightly volatile
Inventory655.2 M624 M214 M
Slightly volatile
Short Term Debt1.5 B1.4 B298.6 M
Slightly volatile
Current Deferred Revenue4.7 M9.2 M4.4 M
Slightly volatile
Net Tangible Assets2.6 B2.5 B1.1 B
Slightly volatile
Capital Surpluse1.5 B2.6 B1.4 B
Slightly volatile
Non Current Liabilities Other19.8 M20.8 M42.2 M
Slightly volatile
Long Term Debt Total852.9 M1.4 B683.7 M
Slightly volatile
Short and Long Term Debt1.5 B1.4 B556.8 M
Slightly volatile
Long Term Investments144.1 M137.2 M34.7 M
Slightly volatile
Capital Lease Obligations121.9 M167.9 M71.9 M
Slightly volatile
Net Invested Capital3.4 B5.2 B2.3 B
Slightly volatile
Net Working Capital2.1 B1.6 B1.4 B
Slightly volatile
Capital Stock251.4 K460 K183 K
Slightly volatile

DexCom Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses4.1 B3.9 B1.5 B
Slightly volatile
Research Development667 M635.3 M303.9 M
Slightly volatile
Total Operating Expenses2.2 B2.1 B895 M
Slightly volatile
Depreciation And Amortization262.9 M250.4 M81.6 M
Slightly volatile
Selling General Administrative1.3 B1.3 B517.1 M
Slightly volatile
Selling And Marketing Expenses234.5 M223.3 M75.3 M
Slightly volatile
Total Revenue4.9 B4.6 B1.7 B
Slightly volatile
Cost Of Revenue1.9 B1.8 B637.3 M
Slightly volatile
Interest Income162 M154.3 M38.6 M
Slightly volatile
Reconciled Depreciation262.9 M250.4 M85.2 M
Slightly volatile

DexCom Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow685.3 M652.6 M398.7 M
Slightly volatile
Depreciation262.9 M250.4 M81.6 M
Slightly volatile
Capital Expenditures433.3 M412.6 M167 M
Slightly volatile
End Period Cash Flow733.3 M698.4 M439.6 M
Slightly volatile
Change To Liabilities366.6 M349.1 M131.4 M
Slightly volatile
Stock Based Compensation145.7 M153.4 M191.5 M
Slightly volatile
Issuance Of Capital Stock21.3 M32.4 M16.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio8.528.9718.923
Slightly volatile
Days Sales Outstanding51.3284.1970.7569
Slightly volatile
Book Value Per Share4.914.682.7243
Slightly volatile
Average Payables1.3 M1.4 M1.3 M
Slightly volatile
Stock Based Compensation To Revenue0.04620.0486159
Slightly volatile
Capex To Depreciation1.821.482.3542
Very volatile
EV To Sales9.069.5418.6882
Slightly volatile
Inventory Turnover5.733.384.5285
Slightly volatile
Days Of Inventory On Hand68.3711292.8221
Slightly volatile
Payables Turnover9.615.317.7558
Slightly volatile
Sales General And Administrative To Revenue7.788.769.5578
Slightly volatile
Research And Ddevelopement To Revenue0.150.160.7615
Slightly volatile
Capex To Revenue0.09720.10.1797
Slightly volatile
Cash Per Share6.025.743.4798
Slightly volatile
Days Payables Outstanding42.5871.1358.619
Slightly volatile
Intangibles To Total Assets0.02880.02240.0312
Slightly volatile
Net Debt To EBITDA1.381.892.3645
Very volatile
Current Ratio1.61.694.8805
Slightly volatile
Tangible Book Value Per Share4.624.42.5874
Slightly volatile
Receivables Turnover7.794.495.9189
Slightly volatile
Graham Number8.0411.616.76
Slightly volatile
Debt To Equity0.61.110.6643
Slightly volatile
Capex Per Share0.840.80.4088
Slightly volatile
Revenue Per Share9.428.974.1631
Slightly volatile
Interest Debt Per Share6.095.82.8715
Slightly volatile
Debt To Assets0.40.460.271
Slightly volatile
Operating Cycle120196164
Slightly volatile
Days Of Payables Outstanding42.5871.1358.619
Slightly volatile
Ebt Per Ebit1.291.3656.9941
Slightly volatile
Long Term Debt To Capitalization0.660.430.4117
Slightly volatile
Total Debt To Capitalization0.540.630.3394
Slightly volatile
Debt Equity Ratio0.61.110.6643
Slightly volatile
Quick Ratio1.41.474.5533
Slightly volatile
Net Income Per E B T0.770.730.9394
Pretty Stable
Cash Ratio0.230.242.351
Slightly volatile
Cash Conversion Cycle77.11125105
Slightly volatile
Days Of Inventory Outstanding68.3711292.8221
Slightly volatile
Days Of Sales Outstanding51.3284.1970.7569
Slightly volatile
Fixed Asset Turnover3.352.594.3544
Slightly volatile
Debt Ratio0.40.460.271
Slightly volatile
Price Sales Ratio8.528.9718.923
Slightly volatile
Asset Turnover0.560.62190.7573
Slightly volatile

DexCom Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap267.1 M254.4 M264.6 M
Slightly volatile
Enterprise Value231.9 M220.9 M229.1 M
Slightly volatile

DexCom Fundamental Market Drivers

Forward Price Earnings29.5858
Cash And Short Term Investments2.6 B

DexCom Upcoming Events

8th of February 2024
Upcoming Quarterly Report
View
25th of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
8th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About DexCom Financial Statements

DexCom investors utilize fundamental indicators, such as revenue or net income, to predict how DexCom Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue9.2 M4.7 M
Total Revenue4.6 B4.9 B
Cost Of Revenue1.8 B1.9 B
Stock Based Compensation To Revenue 0.05  0.05 
Sales General And Administrative To Revenue 8.76  7.78 
Research And Ddevelopement To Revenue 0.16  0.15 
Capex To Revenue 0.10  0.10 
Revenue Per Share 8.97  9.42 
Ebit Per Revenue 0.13  0.14 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether DexCom Inc is a strong investment it is important to analyze DexCom's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact DexCom's future performance. For an informed investment choice regarding DexCom Stock, refer to the following important reports:
How To Invest In DexCom
Details
Is DexCom Stock a good investment?
Details
What is DexCom's Net Worth?
Details
Largest Health Care Equipment & Supplies Companies
View
Largest Health Care Equipment & Services Companies
View
Check out the analysis of DexCom Correlation against competitors.
You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Will Health Care Equipment & Supplies sector continue expanding? Could DexCom diversify its offerings? Factors like these will boost the valuation of DexCom. Projected growth potential of DexCom fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every DexCom data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth
1.099
Earnings Share
1.8
Revenue Per Share
11.544
Quarterly Revenue Growth
0.216
Return On Assets
0.0702
Understanding DexCom Inc requires distinguishing between market price and book value, where the latter reflects DexCom's accounting equity. The concept of intrinsic value—what DexCom's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push DexCom's price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between DexCom's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding DexCom should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, DexCom's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY